You searched for "regulation"

848 results found

A phase II dose-ranging study of mirabegron in patients with OAB

This was a multinational, multicentre, randomised, double–blind, double-dummy, parallel group placebo- and active- controlled phase II study. The study enrolled 1108 men and women aged 18 and over. The criteria were: patients must have had overactive blader (OAB) symptoms for...

Prostate Cancer UK warns of over 8,600 ‘missing men’ as referrals drop by 52,000

The Covid-19 pandemic has led to around 52,000 (28%) fewer urgent prostate cancer referrals in England alone, according to statistics shared by Prostate Cancer UK. It’s estimated that more than 8,600 fewer men started treatment for...

Practising surgery in a war zone: an interview with Dr Volodymyr Melnyk

It is now nine months since the full-scale Russian invasion of Ukraine commenced in late February 2022, with Putin announcing a “special military operation” to “denazify and demilitarise” Ukraine. The rest of the world, however, saw it for what it...

All you need to know about percutaneous nephrolithotomy: supine versus prone and mini versus traditional

Introduction Since the first percutaneous nephrolithotomy (PCNL), the technique has undergone many innovations, including modifications in positioning, miniaturisation of instruments and combination with retrograde intra-renal surgery (see Table 1 for an outline of the history of the technique). Controversy has...

The postcode lottery costing men with prostate cancer years of life

Nearly a third of men miss out on lifesaving treatments for prostate cancer – raising to more than half in worst-hit areas Prostate cancer can be cured if found early, but 31% of men diagnosed with aggressive but curable prostate...

The scent of Ethiopia: a personal story part 2

In May/June 2016 we featured a wonderful account of Zeeshan Aslam’s first trip with Urolink to the Hawassa Referral Hospital in Ethiopia (see here). One year on we are delighted that Zeeshan has once again taken the time to provide...

NOVOGLAN – Conservative Phimosis Management

iMEDicare are pleased to introduce Novoglan, an evidence-based, non-surgical solution for adult phimosis, now available as a reimbursable outpatient treatment under the NHS OPCS-4 code N30.5 (Stretching of the Prepuce), which maps to HRG LB56A. This presents an exciting opportunity...

Balanitis xerotica obliterans

Balanitis xerotica obliterans (BXO) / lichen sclerosus of the male genitalia is a common cause of acquired phimosis, and was first described by Stuhmer in 1928 [1]. It is described in medical literature as a chronic inflammatory condition of unknown...

BAUN Day Summer Educational Event 2025

Attend the BAUN Day Educational Event on the 6th of June. The day incorporates an educational study day and the national BAUN Day - A Day to Celebrate Urology Nurses! If you are early in your urological nursing career, the...

Robotic Urology

This represents a well written and comprehensive tome covering virtually all aspects of kidney, bladder and prostate surgery. The opening chapters deal well with aspects relating to robotic anaesthesia, training and education which I suspect even the most experienced of...

An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences

This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....

Increased use of active surveillance for men with intermediate risk prostate cancer

The optimal management of men with intermediate risk prostate cancer remains unclear and continues to be debated. The authors interrogate the US National Cancer Database for 176,122 men diagnosed with intermediate risk prostate cancer between 2010 and 2016. Of these...